Week in Review: The Latest from PhRMA

Insurance Coverage 101: How can we cut through the insurance clutter and make sure you have access to the treatments and services you and your family need? Check out the latest Catalyst post about...
Read More
Insurance coverage 101

When it comes to health insurance, you have probably heard terms like deductible, copay or coinsurance thrown around. What does it all mean? Cutting through the clutter of health insurance can be a...
Read More
Protecting Medicare Part D’s Extra Help program

For about 11.8 million Medicare Part D low-income beneficiaries, the Extra Help program lowers or waives patient premiums and deductibles while reducing cost sharing for individual prescriptions....
Read More
Highlighting advances in science during Breast Cancer Awareness Month

Breast Cancer Awareness Month is an opportunity to unite as a community to honor breast cancer survivors and raise awareness about progress researchers and clinicians have made in advancing science. ...
Read More
Medicare Monday: New research finds drugs not a key driver of Medicare Part B costs

Over the last several weeks, Medicare Monday has talked about services covered by Medicare Part B and average sales price (ASP), the method for reimbursing drugs covered by Part B. In particular,...
Read More
Week in Review: The Latest from PhRMA

Industry R&D: The biopharmaceutical industry spends more on R&D than the entire National Institutes of Health operating budget. This week’s Fact Check Friday post outlines how much the industry...
Read More
Personalized Medicine: The next health frontier

One of PhRMA’s most important roles is serving as a convener. And earlier this week we joined with The Hill to convene two terrific discussions around personalized – or precision – medicine. We do...
Read More
Fact Check Friday: The truth about Industry’s role in R&D

As a follow-up to this blog we posted last year, PhRMA is excited to share new data that provides a fresh look at the significant investment of America’s biopharmaceutical companies make in R&D. In...
Read More
What makes Valeant different than innovative biopharmaceutical companies?

Much like Turing, Valeant Pharmaceutical’s strategy is more reflective of a hedge fund than an innovative biopharmaceutical company. Valeant’s CEO has stated that the company’s “strategy is quite...
Read More
3 Tiers, 4 Tiers, 5 Tiers and More – A look at tiering in health insurance exchange plans

One size fits all rarely works for clothing, and it turns out, it doesn’t work for prescription drug coverage either. Health insurance plans cover prescription drugs through formularies, which list...
Read More
Clinical Trials Q&A: Improving the recruitment process by listening to patients

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today's challenges and opportunities. The Catalyst welcomes guest...
Read More
Helping Medicare patients manage chronic conditions

For patients living with multiple chronic conditions, managing medications can be a challenge. That’s why Medication Therapy Management (MTM) in Medicare Part D is offered to certain eligible...
Read More
Sharing a Story of Hope

All of us – patients, survivors and loved ones – face challenges from the moment of a disease diagnosis through treatment. And those challenges are personal. Ten years ago, there was no such thing as...
Read More
Clinical Trials Q&A : How does collaboration increase clinical trial awareness and access?

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today's challenges and opportunities. The Catalyst welcomes guest...
Read More
New video: Saving lives and building for the future

Over the last 25 years, medicines have helped change the way patients are treated and helped those diagnosed with debilitating diseases live longer, healthier lives. Not long ago HIV was an acute,...
Read More
Medicare Monday: What goes into Part D premiums?

You’ve heard us talk before about Part D premiums. Check out our 4 things to know about the 2016 Part D premium announcement here. And with the annual open enrollment period now underway, it is...
Read More
Fact Check Friday: Medicaid spending on prescription medicines

This week on Fact Check Friday, we’re talking about Medicaid. Medicaid provides health coverage for low-income and disabled individuals and is jointly funded by states and the federal government. ...
Read More
Our continued commitment to combating Ebola

Since March of 2014, there have been more than 28,000 cases of Ebola in West Africa, with more than 11,000 deaths, according to the World Health Organization (WHO). From the beginning of the...
Read More
Introducing clinical research participation to the everyday person

Clinical trials involve many different people and institutions coming together to better understand disease, biology and the impact of potential medicines. Carefully conducted clinical trials are the...
Read More
A new kind of Chart Pack

I’m excited to introduce our new online Chart Pack, a resource designed to visually demonstrate how much value America’s biopharmaceutical researchers and manufacturers bring to our nation’s broader...
Read More
Ensuring access for Hispanic Americans

Hispanic Heritage Month may be coming to a close, but every day we need to ensure people have access to trusted health care information regardless of the language they speak. This time of year,...
Read More
Local Impact: Improving diabetes care for children in Medicaid

Earlier this fall we looked at how Medicaid beneficiaries adhering to their prescription drug regimens could result in a decline in expensive hospitalizations and emergency room visits, and...
Read More
Medicare Monday: 3 tips for choosing a Medicare Part D plan

This Thursday, October 15 marks the start of another Medicare Open Enrollment period, which runs through Monday, December 7, 2015. Every year Medicare beneficiaries can evaluate their plan choices...
Read More
Week in Review: The Latest from PhRMA

Special Edition Medicare Monday: This week, Richard I. Smith, principal, RIS Consulting and past executive vice president for Policy and Research at PhRMA, shed light on the Medicare Payment Advisory...
Read More
Special Edition Medicare Monday: More context on MedPAC’s analysis of drug costs – Part II
By Rick Smith | October 9, 2015
Richard I. Smith is principal, RIS Consulting and a past executive vice president for policy and research of PhRMA. Yesterday, we looked at MedPAC’s recent presentation on drug spending in Medicare....
Read More
ICYMI: New cholesterol-lowering medicines will not be “budget busters”

In case you missed it, Express Scripts, the nation’s largest pharmacy benefit manager, announced that it will include two new cholesterol-lowering medicines, called PCSK9 inhibitors, on its national...
Read More
340B Spotlight: Rapid growth of contract pharmacies

Last week we covered the basics around contract pharmacies in the 340B program. Today we’re taking a closer look at contract pharmacies as a relatively new source of growth in the program. Contract...
Read More
Special Edition Medicare Monday: More context on MedPAC’s analysis of drug costs
By Rick Smith | October 8, 2015
Richard I. Smith is principal, RIS Consulting and a past executive vice president for policy and research of PhRMA. A few weeks ago, we looked at the Medicare Payment Advisory Commission’s (MedPAC)...
Read More
ICYMI: Higher out-of-pocket costs in health insurance exchange plans compared to employer plans for patients managing chronic conditions

A recent study published in Health Affairs took a look at estimated out-of-pocket expenses for individuals living with chronic conditions if they switched from average employer-sponsored plans to a...
Read More
Highlighting innovation during Mental Illness Awareness Week 2015

Each year, during the first full week of October, organizations across the country work to raise awareness for mental health disorders to educate the public, fight stigma and provide support. Mental...
Read More
4 facts on why drug importation is bad for patients

Ensuring patients have access to needed medicines is critical, but the importation of unapproved medicines, whether from Canada or elsewhere in the world, is the wrong answer. Due to the U.S. Food...
Read More
Medicare Monday: Who Benefits from Part D Extra Help?

We’ve talked before about Medicare Part D’s Extra Help program – also known as Low-Income Subsidies (LIS)—a program designed to help Medicare beneficiaries with limited incomes afford needed...
Read More
Week in Review: The Latest from PhRMA

340B Spotlight: The latest 340B Spotlight explores contract pharmacy arrangements. Learn more about the history of contract pharmacy arrangements and why a policy change in 2010 led to a dramatic...
Read More
340B Spotlight: What are contract pharmacy arrangements?

We’ve been covering 340B a lot in recent weeks, including areas of needed reform: how discounts work, levels of charity care among 340B hospitals and the relatively high rate of 340B hospitals...
Read More